Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

HEPCLUDEX 2 mg powder for solution for injection

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Bulevirtide acetate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Bulevirtide acetate
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

What Hepcludex is Hepcludex contains the active substance bulevirtide, which is an antiviral medicine. What Hepcludex is used for Hepcludex is used to treat long-term (chronic) hepatitis delta virus (HDV) infection in adults and children 3 years of age and older weighing at least 10 kg with compensated liver disease (when the liver is still working well enough). Infection with hepatitis delta virus causes inflammation of the liver. How Hepcludex works HDV uses a particular protein in liver cells to enter the cells. Bulevirtide, the active substance in this medicine blocks the protein and so prevents the HDV from getting into liver cells. This reduces the spread of HDV in the liver and reduces inflammation. 2.

What you need to know before you take it

e Hepcludex

Do not use Hepcludex:

  • if you are allergic to bulevirtide or any of the other ingredients of this medicine (listed in section 6). If you are not sure, speak to your doctor before using this medicine.

VV026

Warnings and precautions Do not stop your treatment with Hepcludex unless your doctor advises you to do so. Stopping the treatment can reactivate the infection and worsen your disease. If this happens, you may need to restart treatment with Hepcludex again. Talk to your doctor or pharmacist before using Hepcludex: 1. if your liver is not working well enough – it is not known how well Hepcludex works in these circumstances; if your liver is not functioning well, using Hepcludex is not recommended. 2. if you have had kidney disease or if tests have shown problems with your kidneys. Before and during treatment, your doctor may order blood tests to check how well your kidneys are working; 3. if you have HIV infection or hepatitis C – it is not known how well Hepcludex works in these circumstances; your doctor may order blood tests to check the status of your HIV or hepatitis C infection Children and adolescents Children under 3 years of age or weighing less than 10 kg should not be treated with Hepcludex. Other medicines and Hepcludex Please tell your doctor if you are using, have recently used, or might use any other medicines. Some medicines can increase side effects of Hepcludex and you should not use them at the same time. This is why you should tell your doctor if you are using any of these medicines: 1. 2. 3. 4. 5.

ciclosporin, a medicine that suppresses the immune system; ezetimibe, used for treating high blood cholesterol; irbesartan, used for treating high blood pressure and heart disease; ritonavir, used to treat HIV infection; sulfasalazine, (used for treating rheumatoid arthritis, ulcerative colitis, and Crohn's disease.

Some medicines can increase or decrease the effects of Hepcludex when used together. In some cases, you may need to have certain tests or your doctor may change the dose or monitor you regularly: 1. 2. 3. 4.

cancer treatments (e.g. dasatinib, docetaxel, ibrutinib, paclitaxel); antihistamine medicines used for allergies (e.g. ebastine, fexofenadine); immune system medicines (e.g. everolimus, sirolimus, tacrolimus); medicines for hepatitis C and HIV treatment (e.g. darunavir, glecaprevir, grazoprevir, indinavir, maraviroc, paritaprevir, saquinavir, simeprevir, tipranavir, voxilaprevir); 5. medicines for diabetes (e.g. glibenclamide, nateglinide, repaglinide); 6. medicines for erectile dysfunction (e.g., avanafil, sildenafil, vardenafil); 7. medicines for treating high blood pressure and heart disease (e.g. olmesartan, telmisartan, valsartan); 8. statin, medicines used for high blood cholesterol (e.g. atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin); 9. thyroid hormones used to treat thyroid problems; 10. alfentanil, an opioid medicine used to treat severe pain; 11. bosentan, used for pulmonary arterial hypertension; 12. buspirone, an anxiety medicine; 13. budesonide, used for asthma and chronic obstructive pulmonary disease; 14. conivaptan and tolvaptan, used to treat hyponatraemia (low sodium levels); 15. darifenacin, used to treat urinary incontinence; 16. dronedarone, heart medicine for cardiac arrhythmias; 17. eletriptan, used for migraine headaches; VV026

18. eplerenone, used for high blood pressure; 19. estrone-3-sulfate a menopausal hormone medicine; 20. felodipine and nisoldipine (heart medicines); 21. lomitapide, used for high blood cholesterol; 22. lurasidone and quetiapine, antipsychotic medicines for psychiatric disorders; 23. midazolam and triazolam, medicines to treat insomnia (inability to sleep) and for anaesthesia (to avoid pain during surgery); 24. naloxegol, used to treat dependence on opioid medicines for severe pain; 25. ticagrelor, anticoagulant to prevent blood clotting. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. You should not use this medicine unless specifically told to by your doctor. If you are a woman of childbearing potential, you should not use this medicine without using an effective method of contraception. Talk to your doctor to decide whether you should breastfeed while using Hepcludex. It is not known whether Hepcludex can pass into breast milk. Therefore, a decision must be made whether to discontinue breast-feeding or to discontinue Hepcludex. Driving and using machines Dizziness and tiredness are side effects which may impair your ability to drive and use machines. If you have any concerns consult your doctor. Hepcludex contains sodium This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially "sodiumfree". 3.

How to take it

Hepcludex

Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. Dosage Hepcludex is to be given once a day, as an injection just under the skin (subcutaneous injection). Your doctor and nurse will show you how to prepare and inject Hepcludex. This package leaflet contains a step-by-step injection guide to help you inject the medicine (see section 7). Recommended dose The recommended dose of Hepcludex in adults is 2 mg once daily. The recommended dose of Hepcludex in patients aged 3 to less than 18 years depends on weight, as outlined in the table below. –

The dose for children aged 3 years or more who weigh 35 kg or more is 2 mg once a day, and the amount to be injected is 1.0 ml. The dose for children aged 3 and over, who weigh at least 25 kg but less than 35 kg is 1.5 mg once a day, and the amount to be injected is 0.75 ml. The dose for children aged 3 and over, who weigh at least 10 kg but less than 25 kg is 1mg once a day, and the amount to be injected is 0.5 ml.

VV026

Your doctor will say how long you need to use the medicine for. If you use more Hepcludex than you should If you think you may have used more than you should, tell your doctor immediately. If you forget to use Hepcludex If less than 4 hours have passed since your missed dose of Hepcludex, take the missing dose as soon as possible and take your next scheduled dose at the usual time. If more than 4 hours have passed since your missed dose of Hepcludex, do not take the missed dose. Take the next dose the following day at the usual time. Do not take a double dose to make up for the missed dose. Tell your doctor if you have missed a dose of Hepcludex. If you stop using Hepcludex If you do not want to use Hepcludex anymore, talk to your doctor before stopping the treatment. Stopping the treatment can reactivate the infection and worsen your disease. Tell your doctor immediately about any changes in symptoms after stopping treatment. If you have any further questions on the use of Hepcludex, ask your doctor or nurse. 4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Please tell your doctor if any of the side effects occur, or if you notice any side effects not listed in this leaflet. The following side effect is very common (this may affect more than 1 in 10 people):

  • headache
  • itching
  • reactions at the injection site that may include swelling, redness, irritation, bruising, itchiness, rash, hardening, infection or local pain The following side effects are common (these may affect up to 1 in 10 people):
  • dizziness
  • nausea
  • tiredness
  • flu-like illness
  • joint pain

VV026

The following side effects are uncommon (these may affect up to 1 in 100 people):

  • allergic reactions, including anaphylactic reaction (sudden life-threatening allergic reaction). Symptoms of allergic reactions can include:
  • shortness of breath or wheezing
  • swelling of the face, lips, tongue or throat (angioedema)
  • skin rashes
  • changes to blood pressure or heart rate. Symptoms of anaphylactic reaction are like those of allergic reaction, but more severe and require immediate medical care. Blood tests may also show:
  • an increase in the level of bile acids in the blood (very common)
  • an increase in white blood cells (eosinophils) (common) Reporting of side effects If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App. By reporting side effects, you can help to provide more information on the safety of this medicine. 5.

How to store it

Hepcludex

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. The expiry date refers to the last day of that month. Store in a refrigerator (2°C -8°C). In order to protect from light, keep the vials in the outer carton. The reconstituted solution should be used immediately. However, if this is not possible it can be stored for up to 2 hours at a temperature of up to 25°C. Important: Do not reuse the vials, syringe, needles or any remaining sterile water for injection. Hepcludex and ancillary supplies are for single use only. Throw away all components after use, including unused sterile water for injection. Do not throw away any medicines or used needles via wastewater or household waste. Ask your pharmacist how to safely dispose medicines and used needles. 6.

Contents of the pack and other information

What Hepcludex contains The active substance is bulevirtide 2 mg. Each vial contains bulevirtide acetate equivalent to 2 mg bulevirtide. The other ingredients are: sodium carbonate anhydrous, sodium hydrogen carbonate, mannitol, hydrochloric acid, sodium hydroxide. What Hepcludex looks like and contents of the pack Bulevirtide is a powder for solution for injection and comes as a white to off-white powder. Each carton contains 30 single doses.

VV026

Marketing Authorisation Holder Gilead Sciences Ltd 280 High Holborn London WC1V 7EE United Kingdom Manufacturer Gilead Sciences Ireland UC IDA Business and Technology Park Carrigtohill Co. Cork Ireland For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Gilead Sciences Ltd Tel: + 44 (0) 8000 113 700 This leaflet was last revised in 02/2026.

VV026

7.

Step-by-step injection guide for patients/caregivers

Before using Hepcludex, you must first read sections 1 – 6 of this package leaflet. Before you begin treatment with this medicine at home, your doctor or nurse will show you how to prepare and inject Hepcludex. This guide shows how to prepare and inject Hepcludex. Speak with your doctor or nurse if you are unclear about anything or you have questions or need more information or help. Take your time to carefully prepare and inject Hepcludex. If your child has been prescribed Hepcludex, but is unable to administer it themselves, please note that all the information in this step-by-step injection guide for administration of Hepcludex is addressed to you, as the child's caregiver. Children or adolescents should only inject themselves following training from a healthcare professional and under supervision of an adult caregiver. Note: The supplies (needles, syringes, sterile water for injection) not included in the Hepcludex carton may slightly differ in size, shape and colour from the figures shown in this step-by-step injection guide. These instructions provide the steps to mix and inject Hepcludex using an example set of supplies. If you have any questions, contact your healthcare provider or pharmacist. Injection sites The best places to inject are the abdomen and upper thighs, shown in the pictures. In order to reduce injection site reactions, you may change the site of Hepcludex injection regularly. Do not inject Hepcludex into the following areas: knee, groin, the lower or inner buttocks, directly over a blood vessel, around the navel (belly button), on scar tissue, a bruise, a mole, a surgical scar, tattoo or burn site, or where there is an injection site reaction. 1. Before you inject 1A Storage Hepcludex vials must be stored in the original packaging in the refrigerator (2- 8 °C) in order to protect Hepcludex from light. 1B Preparing doses b 1C Wash hands Wash your hands well using soap and warm water and dry them with a clean towel. Once your hands are clean, do not touch anything else other than the medicine, supplies and the area around the injection site. 1D Clean vial Wipe the vial top with a new alcohol pad and let the top air-dry. If you touch the rubber top after cleaning it, clean it again with a new alcohol pad.

VV026 VV

2. Mix the injection

2A Draw up sterile water Pick up the syringe. Put the longer needle on. Important! Be sure the capped needle is tight by pushing it down slightly while twisting it clockwise. Pull off the plastic cap. Open the vial of sterile water for injection. Insert the needle in the vial and gently turn the water vial upside down. Make sure the tip of the needle is always below the surface of the water to help keep air bubbles from entering the syringe. Slowly pull the plunger back to get 1.0 ml of sterile water into the syringe. Carefully remove the needle and syringe from the vial. 2B Inject sterile water into the powder Gently tap the Hepcludex vial to loosen the powder. Insert the needle with sterile water all the way into the Hepcludex vial by pushing it straight through the centre of the rubber stopper at a 90° angle. Inject all the sterile water slowly. Remove the needle from the vial and put the syringe and needle somewhere safe. 2C Gently mix Hepcludex Gently tap the Hepcludex vial with your fingertip for 10 seconds to start dissolving the powder. Then gently roll the vial between your hands to ensure thorough mixing. Make sure no powder is stuck to the vial wall. Important! Do not shake the vial. Shaking will make the medicine foam and it will take much longer to dissolve. 2D Inspect Hepcludex Once the powder starts to dissolve, just set it aside and it completely will dissolve. After tapping, it could take up to 3 min to dissolve. 2E Hepcludex ready for injection When mixed completely, the Hepcludex solution should be clear. Important! Completely dissolved Hepcludex should be clear and without foam. If the solution appears foamy or yellowish, allow more time for it to dissolve. If you see bubbles, gently tap the vial until they disappear. If you see any particles in the solution once it is (completely) dissolved, do not use that vial. Contact your doctor or pharmacist that provided it. Reconstituted Hepcludex must be used immediately. VV026 VV

2F Clean vial Clean the Hepcludex vial top again, using a new alcohol pad. Allow it to air dry. 3. Inject a dose 3A Insert needle into vial Pick up the syringe. Reinsert the needle all the way into the Hepcludex vial by pushing it straight through the centre of the rubber stopper at a 90° angle. 3B Draw up Hepcludex Gently turn the vial upside down. Make sure the tip of the needle is always below the surface of the Hepcludex solution to help keep air bubbles from entering the syringe. Double check the amount to inject, using the table called Recommended dose in section 3 of the package leaflet. Slowly pull the plunger to get the amount of liquid you need. 3C Finishing preparation Gently tap or flick the syringe and push/pull the plunger to remove extra air and bubbles. To be sure you end up with the right amount of Hepcludex in the syringe, you may need to pull the plunger past the mark on the syringe. Carefully remove the needle and syringe from the vial. 3D Change and discard the needle Remove the longer needle from the syringe and dispose of it properly into a sharps disposal container so that nobody can be injured. Important! Do not put the plastic cap back on the needle. 3E Attach needle for injection Place the shorter needle on the syringe. Important! Be sure the capped needle is tight by pushing it down slightly while twisting it clockwise. Note: The shorter needle may or may not have a safety shield on the side. 3F Choose the injection site Choose a site different from the one you used for your last injection. VV026 VV

Clean the injection site with a new alcohol pad. Start in the centre, apply pressure and clean in a circular motion, working outward. Important! Allow site to air-dry. 3G Fold back safety shield (if applicable) Note: If there is no safety shield on the injection needle, go directly to Step 3H. Hold the syringe with one hand and fold the safety shield back towards the syringe. Do not remove the needle safety shield from the injection needle. 3H Remove needle cap Carefully pull off the injection needle plastic cap. Do not touch the needle or allow it to touch any other surface. 3I Prepare injection site Pinch and hold a fold of cleaned skin around the injection site 3J Inject Hepcludex Pierce the skin at a 45-degree angle. The needle should be inserted all the way in. Slowly push the plunger all the way to inject Hepcludex . Remove the needle from skin. 3K After injecting, cover needle with safety shield (if applicable) Note: If there is no safety shield on the injection needle, go directly to Step 3L. Place the injection needle safety shield on the work surface. Press the needle toward the safety shield to cover the needle and lock the safety shield. Do not touch the needle. 3L Dispose of the needle properly Remove the needle from the syringe and throw away (dispose of) into the sharps disposal container so that nobody can be injured. Dispose of the syringe (without needle) separately and according to local guidelines. Important! Do not reuse the Hepcludex vial, syringe, needles or any remaining sterile water for injection. Discard the vial after use, including any unused excess liquid. Hepcludex vials and other supplies are for Single Use Only. Throw away (dispose of) all components after use, including unused sterile water for injection.

VV026 VV

Frequently asked questions about HEPCLUDEX 2 mg powder for solution for injection

How do I take HEPCLUDEX 2 mg powder for solution for injection?

HEPCLUDEX 2 mg powder for solution for injection comes as injection containing 2mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in HEPCLUDEX 2 mg powder for solution for injection?

The active substance in HEPCLUDEX 2 mg powder for solution for injection is bulevirtide acetate.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for HEPCLUDEX 2 mg powder for solution for injection, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get HEPCLUDEX 2 mg powder for solution for injection without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Bulevirtide acetate (1 medicine)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Hepcludex is indicated for the treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adult and paediatric patients 3 years of age and older weighing at least 10 kg with compensated liver disease.

4.2. Posology and method of administration

Treatment should be initiated only by a physician experienced in the treatment of patients with HDV infection.

Posology

Bulevirtide should be administered once daily (every 24 hours ± 4 hours) by subcutaneous injection as monotherapy or in co-administration with a nucleoside/nucleotide analogue for treatment of underlying hepatitis B virus (HBV) infection.

The recommended dose of bulevirtide in adult patients is 2 mg once daily.

The recommended dose of bulevirtide in paediatric patients is based on weight as detailed in the Table below.

Dosing for paediatric patients using bulevirtide 2 mg powder for solution for injection

Body Weight (kg)

Dosing of reconstituted bulevirtide 2 mg powder for solution for injection (ml)

Bulevirtide Daily Dose

10 kg to < 25 kg

0.5 ml

1 mg

25 kg to < 35 kg

0.75 ml

1.5 mg

35 kg and above

1 ml

2 mg

Concerning co-administration with nucleoside/nucleotide analogues for treatment of HBV infection, refer to section 4.4.

Duration of treatment

The optimal treatment duration is unknown. Treatment should be continued as long as associated with clinical benefit.

Consideration to discontinue the treatment should be given in case of sustained (6 months) HBsAg seroconversion or loss of virological and biochemical response.

Missed doses

If an injection has been omitted and less than 4 hours have elapsed since the scheduled time, the injection must be performed as soon as possible. The time of the next injection will not be calculated from the time of the "rescue" injection, but according to the injection schedule previously established. It is, therefore, necessary to return to the usual pattern of administration, at the appointed time, the following day.

If an injection has been missed and more than 4 hours have elapsed since the scheduled time, the missed dose should not be administered.

The next injection will take place according to the usual schedule (injection of the prescribed dose without doubling), at the appointed time the next day.

If the injection has been made by mistake more than 4 hours after the scheduled time, the next administration must take place in the usual way (i.e. in accordance with the original schedule).

Special populations

Elderly

No data is available in patients > 65 years.

Renal impairment

No studies have been conducted with bulevirtide in patients with renal impairment.

Renal function should be carefully monitored. Elevation of bile salts may occur during treatment. Due to renal excretion of bile salts, elevation of bile salts may be greater in patients with renal impairment.

Hepatic impairment

No dose adjustment is required for patients with mild hepatic impairment (Child-Pugh-Turcotte class A). The safety and efficacy of bulevirtide in patients with decompensated cirrhosis have not been established (see sections 4.4 and 5.2).

Paediatric population

The safety and efficacy of bulevirtide in patients younger than 18 years of age have not been established in clinical studies. The recommended dosage of bulevirtide for paediatric patients 3 years of age and older weighing at least 10 kg with compensated liver disease is based on population pharmacokinetic/pharmacodynamic modelling and simulation (see section 5.2).

Method of administration

For subcutaneous use only. Bulevirtide may be injected into sites such as the upper thigh, or abdomen.

Appropriate training should be given to the patients self-administering the product or to the caregivers administering the product to minimise the risk of the injection site reactions.

The “Step-by-step injection guide”, provided in the carton, must be followed carefully by the patient or the caregiver.

For instructions on reconstitution of the medicinal product before administration, see section 6.6.

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4. Special warnings and precautions for use

HDV and HBV genotype

HDV genotype 1 was predominant in the clinical trials population. It is not known whether HDV or HBV genotype affects the clinical efficacy of bulevirtide.

Decompensated liver disease

The pharmacokinetics, safety and efficacy of bulevirtide in patients with decompensated cirrhosis has not been established. The use in patients with decompensated liver disease is not recommended.

Co-infection with HBV

The underlying HBV infection should be simultaneously managed according to current treatment guidelines. In the clinical study of bulevirtide MYR202, only patients with signs of active hepatitis despite nucleoside/nucleotide analogue treatment were included; tenofovir disoproxil fumarate was co-administered with bulevirtide. Close monitoring of HBV DNA levels is recommended.

Hepatitis exacerbations after treatment cessation

Discontinuation of treatment with bulevirtide may lead to reactivation of HDV and HBV infections and severe acute exacerbations of hepatitis, especially in patients with cirrhosis who may be at increased risk of more severe flares or progression to hepatic decompensation. In case of treatment discontinuation, careful monitoring of hepatic function with both clinical and laboratory follow-up should be performed for at least 6 months after discontinuation, including monitoring transaminase levels, as well as HBV DNA and HDV-RNA viral load. In certain circumstances, resumption of antiviral therapy may be warranted.

Co-infection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV)

No data are available from HIV or HCV co-infected patients.

Excipients

This medicine contains less than 1 mmol of sodium (23 mg) per ml, that is to say essentially "sodium-free".

4.5. Interaction with other medicinal products and other forms of interaction

In vitro, it has been shown, that certain medicinal products can inhibit bulevirtide target sodium-taurocholate co-transporting polypeptide (NTCP). The co-administration of such medicinal products (e.g. sulfasalazin, irbesartan, ezetimibe, ritonavir, and ciclosporin A) is not recommended.

As a precautionary measure, close clinical monitoring is warranted when NTCP substrates (e.g. estrone-3-sulfate, fluvastatin, atorvastatin, pitavastatin, pravastatin, rosuvastatin, and thyroid hormones) are co-administered with bulevirtide. When possible, co-administration of these substrates should be avoided.

In vitro an inhibition of OATP1B1/3 transporters by bulevirtide was observed, albeit only at a concentration ≥ 0.5 µM, which is only reached in vivo after administration of high bulevirtide doses (10 mg subcutaneous). The clinical relevance of these findings is unknown. As a precautionary measure, close clinical monitoring is warranted when OATP1B1/3 substrates (e.g. atorvastatin, bosentan, docetaxel, fexofenadine, glecaprevir, glyburide (glibenclamide), grazoprevir, nateglinide, paclitaxel, paritaprevir, pitavastatin, pravastatin, repaglinide, rosuvastatin, simeprevir, simvastatin, olmesartan, telmisartan, valsartan, voxilaprevir) are co-administered. When possible, co-administration of these substrates should be avoided.

In a clinical study in healthy subjects, co-administration of tenofovir and bulevirtide revealed no impact on tenofovir pharmacokinetics.

No CYP inhibition by bulevirtide was observed in vitro at clinically relevant concentrations. However, in a clinical study, an approximately 40% increase in geometric mean of partial AUC2-4h values of co-administered midazolam (CYP3A4 substrate) was observed in combination of high dose bulevirtide (10 mg) and tenofovir (245 mg), whereas no significant influence on midazolam AUC2-4h was detected for tenofovir alone. As a precautionary measure, close clinical monitoring is warranted for co-administered narrow-therapeutic-index drugs which are sensitive CYP3A4 substrates (e.g. cyclosporine, carbamazepine, simvastatin, sirolimus, and tacrolimus).

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no or limited amount of data from the use of bulevirtide in pregnant women.

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity.

As a precautious measure, it is preferable to avoid the use of bulevirtide during pregnancy and in women of child-bearing potential not using contraception.

Breast-feeding

It is unknown whether bulevirtide is excreted in human milk. Therefore, a decision must be made whether to discontinue breast-feeding or to discontinue / abstain from treatment with bulevirtide, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Fertility

No human data on the effect of bulevirtide on fertility are available. In animal studies, no effects of bulevirtide on male or female mating and fertility were noted.

4.7. Effects on ability to drive and use machines

The product has minor influence on the ability to drive and use machines. Patients should be informed that dizziness has been reported during treatment with bulevirtide (see section 4.8).

4.8. Undesirable effects

Summary of the safety profile

The most frequently reported adverse reactions are increase in bile salts (very common), headache (very common), pruritus (very common) and injection site reactions (very common).

Increases in bile salts were usually asymptomatic and reversible upon treatment discontinuation.

The most frequently reported serious adverse reaction is an exacerbation of hepatitis after discontinuation of bulevirtide, possibly related to virologic rebound after discontinuation of treatment (see section 4.4).

Tabulated list of adverse reactions

The following adverse reactions are based on pooled data from clinical studies in adults and post-marketing experience.

Adverse reactions are listed below by system organ class and frequency. Frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100).

Frequency

Adverse reaction

Blood and lymphatic system disorders

Common

Eosinophilia

Immune system disorders

Uncommon

Hypersensitivity, including anaphylactic reactiona

Nervous system disorders

Very common

Headache

Common

Dizziness

Gastrointestinal disorders

Common

Nausea

Hepatobiliary disorders

Very common

Total bile salts increased

Skin and subcutaneous tissue disorders

Very common

Pruritus

Musculoskeletal and connective tissue disorders

Common

Arthralgia

General disorders and administration site conditions

Very common

Injection site reactionsb

Common

Fatigue

Common

Influenza like illness

a Adverse reaction identified through post-marketing surveillance

b Includes injection site erythema, injection site reaction, injection site pain, injection site induration, injection site swelling, injection site rash, injection site haematoma, injection site pruritus and injection site dermatitis

Description of selected adverse reactions

Total Bile Salts Increased

Asymptomatic bile salt elevations, associated with the mechanism of action of bulevirtide, were very commonly observed in clinical studies of bulevirtide; the bile salt elevations resolved upon discontinuation of bulevirtide treatment.

Due to renal excretion of bile salts, elevation of bile salts may be greater in patients with renal impairment.

Injection Site Reactions

Bulevirtide is intended for subcutaneous injection which is associated with risks for injection site reactions including swelling, redness, irritation, itchiness, infection, haematoma, rash, induration and local pain. These local reactions are more likely to appear if the injection is accidentally misplaced or the solution is accidentally misdirected to the soft tissue.

Eosinophilia

Increases in eosinophil counts were commonly observed in patients receiving bulevirtide treatment; there were no associated clinical sequelae, hepatic adverse reactions, or significant liver-related laboratory abnormalities.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

There are no data on human overdose with bulevirtide. If overdose occurs, the patient must be monitored for evidence of toxicity and given standard supportive treatment as necessary.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

  • HEPCLUDEX 2 mg prescriptionBULEVIRTIDUM · injection / infusion

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

  • HepcludexBulevirtidum · injection / infusion

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about HEPCLUDEX 2 mg powder for solution for injection. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

📋 Official guidance mentioning this medicine

→ Bulevirtide for treating chronic hepatitis D (NICE · 2023)
Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →